This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Dutasteride in androgenic alopecia (AGA)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Dutasteride in androgenic alopecia:

  • dutasteride is a dual 5alpha-reductase
    • has been used for the treatment of male androgenetic alopecia
      • evidence shows that dutasteride seems to provide a better efficacy compared with finasteride in treating an drogenetic alopecia. The two drugs appear to show similar rates of adverse reactions, especially in sexual dysfunction (1)

      • a prospective study investigating sexual dysfunction associated with dusteride use for androgenic alopecia in men found (2):
        • incidence of sexual adverse events was approximately twofold higher in the dutasteride group (16%) than the placebo group (8%) during the double-blind period; the overall incidence of sexual adverse events was lower (5%) during the open-label period
        • all adverse events were mild to moderate in severity and considered treatment-related
        • adverse events resolved while on study treatment or after the end of treatment and did not lead to treatment discontinuation.

  • comparing treatments for male androgenic alopecia
    • analysis of 23 trials indicate 5mg/d oral dutasteride has highest probability of being most efficacious treatment, followed by (in decreasing order of efficacy): 5mg/d oral finasteride (OF), 5mg/d oral minoxidil (OM), 1mg/d OF, 5% topical minoxidil (TM), 2% TM, & 0.25mg/d OM (3)

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.